Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 May;65(5):703–707. doi: 10.1038/bjc.1992.148

In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.

M Ripamonti 1, G Pezzoni 1, E Pesenti 1, A Pastori 1, M Farao 1, A Bargiotti 1, A Suarato 1, F Spreafico 1, M Grandi 1
PMCID: PMC1977399  PMID: 1586598

Abstract

FCE 23762 is a new doxorubicin derivative obtained by appending a methoxymorpholinyl group at position 3' of the sugar moiety. The compound is greater than 80 times more potent than doxorubicin, it is highly lipophilic, and presents equivalent anti-tumour activity when administered by i.p., i.v. or oral route. The pattern of anti-tumour activity of FCE 23762 differs from that of doxorubicin in maintaining anti-tumour activity against two P388 murine leukaemia sublines resistant to doxorubicin and, although at borderline levels of efficacy, against LoVo human colon adenocarcinoma resistant to doxorubicin. FCE 23762 exhibits remarkable efficacy against MX-1 human mammary carcinoma, with most treated mice being cured both after i.v. and oral treatment. Anti-tumour activity was also observed against L1210 murine leukaemia and two sublines resistant to cis-platinum and melphalan, M5076 murine reticulosarcoma, MTV murine mammary carcinoma and N592 human small cell lung cancer.

Full text

PDF
703

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbieri B., Giuliani F. C., Bordoni T., Casazza A. M., Geroni C., Bellini O., Suarato A., Gioia B., Penco S., Arcamone F. Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin. Cancer Res. 1987 Aug 1;47(15):4001–4006. [PubMed] [Google Scholar]
  2. Beck W. T. Multidrug resistance and its circumvention. Eur J Cancer. 1990 Apr;26(4):513–515. doi: 10.1016/0277-5379(90)90028-r. [DOI] [PubMed] [Google Scholar]
  3. Beck W. T. The cell biology of multiple drug resistance. Biochem Pharmacol. 1987 Sep 15;36(18):2879–2887. doi: 10.1016/0006-2952(87)90198-5. [DOI] [PubMed] [Google Scholar]
  4. Coley H. M., Twentyman P. R., Workman P. 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer. 1990;26(6):665–667. doi: 10.1016/0277-5379(90)90112-7. [DOI] [PubMed] [Google Scholar]
  5. Di Marco A., Lenaz L., Casazza A. M., Scarpinato B. M. Activity of adriamycin (NSC-123127) and daunomycin (NSC-82151) against mouse mammary carcinoma. Cancer Chemother Rep. 1972 Apr;56(2):153–161. [PubMed] [Google Scholar]
  6. Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137–171. doi: 10.1146/annurev.bi.58.070189.001033. [DOI] [PubMed] [Google Scholar]
  7. Facchetti I., Grandi M., Cucchi P., Geroni C., Penco S., Vigevani A. Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines. Anticancer Drug Des. 1991 Nov;6(5):385–397. [PubMed] [Google Scholar]
  8. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S. L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989 Jan 18;81(2):116–124. doi: 10.1093/jnci/81.2.116. [DOI] [PubMed] [Google Scholar]
  9. Grandi M., Geroni C., Giuliani F. C. Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br J Cancer. 1986 Sep;54(3):515–518. doi: 10.1038/bjc.1986.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Grandi M., Pezzoni G., Ballinari D., Capolongo L., Suarato A., Bargiotti A., Faiardi D., Spreafico F. Novel anthracycline analogs. Cancer Treat Rev. 1990 Sep;17(2-3):133–138. doi: 10.1016/0305-7372(90)90037-g. [DOI] [PubMed] [Google Scholar]
  11. Izumoto S., Arita N., Hayakawa T., Ohnishi T., Taki T., Yamamoto H., Ushio Y. Effect of MX2, a new morpholino anthracycline, against experimental brain tumors. Anticancer Res. 1990 May-Jun;10(3):735–739. [PubMed] [Google Scholar]
  12. Johnson R. K., Chitnis M. P., Embrey W. M., Gregory E. B. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep. 1978 Oct;62(10):1535–1547. [PubMed] [Google Scholar]
  13. Kaye S. B. The multidrug resistance phenotype. Br J Cancer. 1988 Dec;58(6):691–694. doi: 10.1038/bjc.1988.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Odaimi M., Andersson B. S., McCredie K. B., Beran M. Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia. Cancer Res. 1986 Jul;46(7):3330–3333. [PubMed] [Google Scholar]
  15. Rothenberg M., Ling V. Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst. 1989 Jun 21;81(12):907–910. doi: 10.1093/jnci/81.12.907. [DOI] [PubMed] [Google Scholar]
  16. Watanabe M., Komeshima N., Nakajima S., Tsuruo T. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Cancer Res. 1988 Dec 1;48(23):6653–6657. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES